New
Boost your weekend mood with some good news:
The European Medicines Agency expressed a positive opinion on Opzelura earlier this week. The green light opens the fast track for it to become the first ‘official’ vitiligo therapy in the EU. Incyte has been eagerly awaiting this approval ever since the it’s drug was registered by the US FDA in July 2022.
Opzelura, a 1.5% ruxolitinib cream, is a sister medication to Incyte's JAK inhibitor, Jakafi. It is used to treat nonsegmental vitiligo in patients ages 12 and older, with primarily facial involvement. The cream is meant to be applied twice a day on affected areas of up to 10% of the body’s surface area, and patients may need to use it for up to 24 weeks in order to see the best results.
🔬RESEARCH UPDATE
VYNE Therapeutics Inc. has recently announced positive results from the Phase 1a/b clinical trial evaluating its novel BET inhibitor for vitiligo.
Prof. Mark Lebwohl, MD, shares updates on recent clinical breakthroughs and agents in the drug development pipeline. Read or watch interview with Dermatology Times at Winter Clinical Miami, held on February 20, 2023.
👋 LET'S MEET
- 🇰🇿 The World Vitiligo Day 2023 headquarters will be set in Almaty, Kazakhstan, under the leadership of Dr. Aliya Kassumkhanova. The preparations are in full swing, with incredible support from volunteers across the country. June 23-25, 2023.
- 🇷🇴 XII edition of Iasi Dermatological Spring will present the most impactful topics in dermatology, - including vitiligo session by the VRF. April 27, 2023.
📺 WATCH IT
The first Public Service Announcement (PSA) for vitiligo went live across all major networks. Dr. Pearl Grimes emphasizes in a 1-minute video the importance of talking to a dermatologist about individual goals and management options.
To date, this PSA has been picked up on 432 websites and 29,304 TV airings including top networks such as CNN, Fox News, CBS, MSNBC and more. Let's share this far and wide to hit over 800M views!
Wishing you a great weekend,
Yan Valle,
CEO VR Foundation
FAQOther Questions
- What tests should be done?
A well-trained dermatologist should be able to diagnose vitiligo and distinguish it from contact leukoderma or more than twenty other conditions with similar skin appearance bas...
- I have vitiligo: will my children have vitiligo, too?
Children born to parents who both have the disorder are more likely to develop vitiligo. However, most children will not get vitiligo even if one parent has it. In children with...
- What causes vitiligo?
Surprisingly, the causes of vitiligo are yet to be precisely established. Researchers know the cause is pre-wired in your genes, just waiting for a bad luck moment. In about hal...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.